Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir vs Lopinavir/Ritonavir in Second-Line HIV-1 Treatment
NCT02227238Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Dec 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <50 Copies Per Milliliter at Week 48. Started Dec 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02227238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227238.